コンテンツへスキップ
Merck
  • Ex vivo 18F-fluoride uptake and hydroxyapatite deposition in human coronary atherosclerosis.

Ex vivo 18F-fluoride uptake and hydroxyapatite deposition in human coronary atherosclerosis.

Scientific reports (2020-11-21)
Alastair J Moss, Alisia M Sim, Philip D Adamson, Michael A Seidman, Jack P M Andrews, Mhairi K Doris, Anoop S V Shah, Ralph BouHaidar, Carlos J Alcaide-Corral, Michelle C Williams, Jonathon A Leipsic, Marc R Dweck, Vicky E MacRae, David E Newby, Adriana A S Tavares, Stephanie L Sellers
要旨

Early microcalcification is a feature of coronary plaques with an increased propensity to rupture and to cause acute coronary syndromes. In this ex vivo imaging study of coronary artery specimens, the non-invasive imaging radiotracer, 18F-fluoride, was highly selective for hydroxyapatite deposition in atherosclerotic coronary plaque. Specifically, coronary 18F-fluoride uptake had a high signal to noise ratio compared with surrounding myocardium that makes it feasible to identify coronary mineralisation activity. Areas of 18F-fluoride uptake are associated with osteopontin, an inflammation-associated glycophosphoprotein that mediates tissue mineralisation, and Runt-related transcription factor 2, a nuclear protein involved in osteoblastic differentiation. These results suggest that 18F-fluoride is a non-invasive imaging biomarker of active coronary atherosclerotic mineralisation.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
抗オステオポンチン ウサギ宿主抗体, affinity isolated antibody, buffered aqueous solution